53
Views
12
CrossRef citations to date
0
Altmetric
Miscellaneous

The role of quantitative PCR for the immune monitoring of cancer patients

, , &
Pages 557-564 | Published online: 23 Feb 2005

Bibliography

  • MARINCOLA FM, JAFFE EM, HICKLIN DJ, FERRONE S: Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. (2000) 74:181–273.
  • JAGER D, JAGER E, KNUTH A: Vaccination for malignant melanoma: recent developments. Oncology (2001) 60:1–7.
  • NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med (1998) 4:328–332.
  • ROSENBERG SA, YANG JC, SCHWARTZENTRUBER D et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. (1998) 4:321–327.
  • MARCHAND M, VAN BAREN N, WEYNANTS P et al.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-Al. Int. Cancer (1999) 80:219–230.
  • LAU R, WANG F, JEFFERY G et al.: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. Immunother. (2001) 24:66–78.
  • PANELLI MC, WUNDERLICH J, JEFFRIES J et al.: Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma associated antigens MART-1 and gp100. Immunother. (1999) 23:487–498.
  • CORMIER JN, SALGALLER ML, PREVETTE T et al.: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/ Melan A. Cancer J. Sci. Am. (1997) 3:37-44. See comments.
  • MARINCOLA FM, WANG E, HERLYN M, SELIGER B, FERRONE S: Tumors as elusive targets for immunotherapy. Lancet Onc. (2002). In press.
  • SZNOL M, MARINCOLA FM: Principles of immune monitoring in cancer vaccine trials. In: Principles and Practice of the Biologic Therapy of Cancer, (3rd edn). Rosenberg SA (ed.), Lippincott Williams & Wilkins, Philadelphia (2000):617–631.
  • •Extensive review about immune monitoring strategies.
  • HEID CA, STEVENS J, LIVAK KJ, WILLIAMS PM: Real time quantitative PCR. Cenome Res. (1996) 6:986–994.
  • ••Original article describing the principle ofqRT-PCR.
  • KRUSE N, PETTE M, TOYKA K, RIECKMANN P: Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. Immunol. Methods (1997) 210:195–203.
  • HOLLAND P, ABRAMSON R: Detection of specific polymerase chain reaction product by utilizing the 5' to 3 exonuclease activity of Thermas Aguaticas DNA polymerase. Proc. Natl. Acad. Sci. USA (1991) 88:7276–7280.
  • KAMMULA US, MARINCOLA FM, ROSENBERG SA: Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. Nati Cancer Inst. (2000) 92:1336–1344.
  • KAMMULA US, LEE KH, RIKER AI et al: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. Immunol. (1999) 163:6867–6879.
  • ••Original article describing the utilisation of qRT-PCR for the immune monitoring of cancer patients. In particular, the principle of ex vivo stimulation of lymphocytes and the analysis of gene expression profile in FNAs was described.
  • OHNMACHT GA, WANG E, MOCELLIN S et al.: Short term kinetics of tumor antigen expression in response to vaccination. Immunol. (2001) 167:1809–1820.
  • NIELSEN M-B, MONSURRO V, MIGUELSE S et al.: Status of activation of circulating vaccine-elicited CD8+ T cells. Immunol. (2000) 165:2287–2296.
  • •This manuscript compares the relative sensitivity and accuracy of various immune monitoring methods including qRT-PCR.
  • MOCELLIN S, OHNMACHT GA, WANG E, MARINCOLA FM: Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int. J. Cancer (2001) 93:236–242.
  • PEREZ-DIEZ A, SPIESS PJ, RESTIFO NP, MATZINGER P, MARINCOLA FM: Intensity of the vaccine-elicited immune response determines tumor clearance. Immunol. (2002) 168:338–347.
  • ••This manuscript describes the utilisation of qRT-PCR for the analysis of murine immune responses.
  • HOUSSEAU F, LINDSEY KR, OBERHOLTZER SD et al.: Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full length tyrosinase protein in vaccinated melanoma patients. Submitted 2002.
  • ••This manuscript describes the utilisation ofqRT-PCR in an autologous antigen presenting system designed to identify antigen-reactivity associated with different HLA alleles expressed by individual patients.
  • HEMPEL DM, SMITH KA, CLAUSSEN KA, PERRICONE MA: Analysis of cellular immune responses in the peripheral blood of mice using real-time RT-PCR. I Immunol. Methods (2002) 259:129-38 This manuscript describes the utilisation of qRT-PCR for the analysis of murine immune responses ex vivo utilising peripheral blood and without requiring sacrifice of the animals.
  • PROVENZANO M, ROSSI CR, MOCELLIN S: The usefulness of quantitative real time PCR in immunogenetics. ASHI Quarterly (2001) 25:89–91.
  • KEILHOLZ U, WEBER J, FINKE Jet al.: Immunologic monitoring of cancer vaccine therapy: results of a Workshop sponsored by the Society of Biological Therapy. Immunother (2002). In press.
  • ••This manuscript represents a consensuspaper on the comparison of various immune monitoring strategies.
  • BLASCHKE V, REICH K, BLASCHKE S, ZIPPRICH S, NEUMANN C: Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: validation of a new real-time RT-PCR technology. j. Immunol. Methods (2000) 246:79–90.
  • YIN JL, SHACKEL NA, ZEKRY A et al.: Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. Immunol. Cell Biol. (2001) 79:213–221.
  • WANG E, MILLER L, OHNMACHT GA, LIU E, MARINCOLA FM: High fidelity mRNA amplification for gene profiling using cDNA microarrays. Nat. Biotech. (2000) 17:457–459.
  • WANG E, MILLER LD, OHNMACHT GA et al.: Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. (2002). In press.
  • WANG E, MARINCOLA FM: cDNA microarrays and the enigma of melanoma immune responsiveness. Cancer j (2001) 7:16–23.
  • ALTMAN JD, MOSS PH, GOULDER PR et al.: Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 274:94-96. Published erratum appears in Science (1998) 280(5371):1821.
  • LEE K-H, WANG E, NIELSEN M-B et al:Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to M vitro stimulation but does not lead to tumor regression. Immunol. (1999) 163:6292–6300.
  • PROVENZANO M, MOCELLIN S, BETTINOTTI et al.: Identification of immune dominant cytomegalovyrus epitopes using quantitative real-time PCR to measure interferon-y production by peptide stimulated peripheral blood mononuclear cells. Immunother. (2002). In press.
  • •This manuscript describes the utilisation of qRT-PCR for the detection of unknown irnmunodominant epitopes directly testing circulating lymphocytes ex vivo.
  • EMMERT-BUCK MR, BONNER RE SMITH PD et al.: Laser capture micro-dissection. Science (1996) 274:998–1001.
  • TANAKA N, KIMURA H: Quantitative analysis of cytomegalovirus load using a real-time PCR assay. Med. Virol. (2000) 60:455–462.
  • GAULT E, MICHEL Y: Quantification ofhuman cytomegalovirus DNA by real time PCR. Clin. Microbial. (2001) 39:772–775.
  • BRECHTUEHL K, WHALLEY S: A rapid real time quantitative polymerase chain reaction for hepatitis B virus. .1 Virol. Methods (2001) 93:105–113.
  • OHGA S, KUBO ENA: Quantitative monitoring of circulating Epstein-Barr virus DNA for predicting the development of posttransplantation lymphoproliferative disease. hat. J. Hematol. (2001) 73:323–326.
  • LIMAYE A, HUANG MLW: Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem cell transplant recipients. Inf. Dis. (2001) 183:377–382.
  • CHEN XPQ, STOW P: Quantification ofminimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real time PCR assay. Leukemia (2001) 15:166–170.
  • TOKUNAGA E, MAEHARA Y: Application of quantitative RT-CR using Taqman technology to evaluate the expression of CK 18 mRNA in various cell lines. I Exp. Clin. Cancer Res. (2000) 19:375–381.
  • PATEL L, CHARLTON SJ, CHAMBERS JK, MACPHEE CH: Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. Cytokine (2001) 14:27-36. Expert Op/n. Biol. Ther. (2002) 2(5)
  • WEISER TS, OHNMACHT GA, GUO et al.: Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann. Thor. Sorg. (2001) 71:295–301.
  • DAS H, KOIZUMI T, SUGIMOTO T, AKRABORTY S, HIMURA T, SHIMURA R: Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br. J. Cancer (2000) 82:1682–1628.
  • MONSURRO V, NIELSEN M-B, PEREZ-DIEZ A et al.: Kinetics of TCR use in response to repeated epitope-specific immunization. J. branunol. (2001) 166:5817–5825.
  • WANG E, MARINCOLA FM: A natural history of melanoma: serial gene expression analysis. branunol. Today(2000) 21:619–623.
  • MOCELLIN S, WANG E, MARINCOLA FM: Cytokine and immune response in the tumor microenvironment. branunother. (2001) 24:392–407.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.